| Patient | Frida Kahlo |
|---|---|
| Date of birth | 1907-07-06 |
| Identifiers | MRN HR-NI011-SYN-TD; SSN (made up) 000-11-4390 |
| Document date | 1944-10-29 |
| Author | Marisol Ortega, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Six-week review of function, mood, and the opioid taper. [S]
Ms. Kahlo returns six weeks after her first visit and two weeks after her oxycodone was reduced to 52.5 MME a day. She has had no yawning, gooseflesh, stomach cramps, diarrhea, restlessness, or loss of sleep beyond her usual. Her pain has not worsened, and her PEG is 5.3, 27 percent below the 7.3 she scored at intake. With the shoe lift she now stands at the easel for 25 to 30 minutes at a time. She goes to physical therapy twice a week and to cognitive behavioral therapy weekly, and she has had no falls. She takes acetaminophen 1 g three times a day. She asks when the next reduction will be and wants it to stay slow. [S]
| Element | Detail |
|---|---|
| Taper | Two weeks at 52.5 MME a day; no withdrawal symptoms |
| PEG | 5.3, 27 percent below intake |
| Function | Stands 25 to 30 minutes at the easel with the shoe lift |
| Rehabilitation | Physical therapy twice weekly; cognitive behavioral therapy weekly |
| Safety | No falls; no sedation |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No sweats, chills, or sleep change |
| Gastrointestinal | Negative | No stomach cramps, diarrhea, nausea, or constipation |
| Musculoskeletal | Positive | Back, pelvic, and ankle pain, no worse since the reduction; no falls |
| Neurological | Positive | Burning in the right leg, less than at intake; no new weakness; no bladder or bowel control change |
| Psychiatric | Negative | Mood steady; PHQ-9 score 4 with item 9 scored 0; no anxiety or restlessness |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Oxycodone 10 mg oral tablet, one tablet every 6 hours as needed for pain, no more than four a day (60 MME a day) | One tablet by mouth every 6 hours as needed for pain; no more than 4 tablets a day | Oral route | 1942-03-04 to 1944-10-15 | completed | S |
| Oxycodone 10 mg oral tablet, one tablet three times daily as needed for pain | One tablet by mouth three times daily as needed for pain | Oral route | 1944-10-15 | active | S |
| Oxycodone 5 mg oral tablet, one tablet at bedtime as needed for pain | One tablet by mouth at bedtime as needed for pain | Oral route | 1944-10-15 | active | S |
| Duloxetine 30 mg delayed-release oral capsule, one capsule daily | One capsule by mouth daily | Oral route | 1944-09-17 to 1944-10-01 | completed | S |
| Duloxetine 60 mg delayed-release oral capsule, one capsule daily | One capsule by mouth daily | Oral route | 1944-10-01 | active | S |
| Acetaminophen 500 mg oral tablet, two tablets three times daily | Two tablets by mouth three times daily; no more than 3,000 mg a day | Oral route | 1944-09-17 | active | S |
| Diclofenac sodium 1% topical gel, 2 g to the right ankle four times daily | Apply 2 g to the right ankle and foot four times daily | Topical route | 1944-09-17 | active | S |
| Cholecalciferol (vitamin D3) 2,000 units oral tablet, one tablet daily | One tablet by mouth daily | Oral route | 1944-09-17 | active | S |
| Naloxone 4 mg nasal spray, one spray into one nostril for suspected opioid overdose; may repeat in the other nostril | For suspected opioid overdose: one spray into one nostril and call 911; if there is no response after 2 to 3 minutes, give a second spray in the other nostril | Nasal route | 1944-09-17 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1944-10-29 | Body height | 160 | cm | S |
| 1944-10-29 | Body weight | 50.5 | kg | S |
| 1944-10-29 | Body mass index (BMI) [Ratio] | 19.7 | kg/m2 | S |
| 1944-10-29 | Systolic blood pressure | 116 | mm[Hg] | S |
| 1944-10-29 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 1944-10-29 | Heart rate | 76 | /min | S |
| 1944-10-29 | Respiratory rate | 14 | /min | S |
| 1944-10-29 | Body temperature | 36.6 | Cel | S |
| 1944-10-29 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1944-10-29 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 7-35 U/L | Normal | S |
| 1944-10-29 | Mean score [PEG] | 5.3 | {score} | S | ||
| 1944-10-29 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S |
Vital signs recorded on 1944-10-29; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Alert and not sedated |
| Eyes | Pupils equal, normal in size, and reactive; no tearing |
| Skin | No sweating or gooseflesh |
| Back | Lumbar paraspinal tenderness, less than at intake |
| Right ankle | Bony enlargement and reduced motion; no effusion |
| Gait | Cane and shoe lift; steady |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Chronic low back and pelvic pain after remote spinal and pelvic fractures and spinal surgery, with neuropathic features in the right leg; linked to the documented 1843 injuries | active | confirmed | G89.21 | S — Synthetic modern diagnosis linked to the documented injuries; the neuropathic interpretation is R. |
| Post-traumatic osteoarthritis of the right ankle and foot after multiple leg fractures and a foot dislocation | active | confirmed | M19.171 | S — Synthetic diagnosis confirmed on the synthetic ankle X-ray. |
| Right leg weakness, atrophy, and shortening after childhood poliomyelitis; a congenital spinal anomaly has been proposed retrospectively | active | provisional | B91 | S — Synthetic modern coding of the documented childhood diagnosis; the alternative remains R. |
| Long-term opioid therapy for chronic pain, 60 MME a day at intake | active | confirmed | Z79.891 | S — Synthetic modern medication status; not a historical assertion. |
| Vitamin D deficiency | active | confirmed | E55.9 | S — Synthetic finding from the baseline 25-hydroxyvitamin D. |
| Acute viral upper respiratory infection (common cold), resolved without antibiotics | resolved | confirmed | J06.9 | S — Synthetic intercurrent illness at an unscheduled visit; it does not echo a documented illness. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | PEG pain, enjoyment of life, and general activity score | Every visit | Completed today | 5.3, 27 percent below intake; the 30 percent goal continues |
| Survey | PHQ-9 depression score, with item 9 | Every 2 to 4 weeks during active treatment | Completed today | 4, with item 9 scored 0 |
| Laboratory | ALT on regular acetaminophen | Periodically when acetaminophen approaches 3 g a day | Completed today | 24 U/L, normal |
| Medication safety | Opioid withdrawal symptoms | At each contact after a reduction | Completed today | None, here or at last week's visit |
| Medication safety | Opioid benefits and harms: function, sedation, constipation, falls | Every visit during a taper; at least every 3 months | Completed today | Function better; no sedation, constipation, or falls |
| Medication safety | Taper step | About 10 percent a month for long-term therapy, adjusted to her response | Up to date | Next step due in about two weeks |
| Medication safety | Prescription drug monitoring program check | Before each opioid prescription; at least every 3 months | Up to date | Checked at last week's visit: a single prescriber |
| Laboratory | Urine drug test, with consent | Before long-term therapy, then at least annually | Up to date | At intake; repeat within a year |
| Medication safety | Opioid use disorder assessment | Before tapering and whenever concerns arise | Up to date | No concerns since the assessment two weeks ago |
| Medication safety | Naloxone at home, with a family member trained | Offer when starting or continuing opioids; review each visit | Up to date | At home |
| Medication safety | Concurrent benzodiazepines or other sedatives | Every visit | Completed today | None |
| Examination | Fall risk | Every visit while on opioids and duloxetine | Up to date | Timed Up and Go 14 seconds last week; no falls |
| Examination | Right ankle examination: range of motion, effusion, alignment | Every visit | Completed today | Unchanged; no effusion |
| Imaging | Right ankle radiograph | Only for diagnostic uncertainty, clinical change, or surgical planning | Not indicated | No clinical change |
| Laboratory | CBC, creatinine, and blood pressure for chronic oral NSAID use | Every 6 to 12 months on oral NSAIDs | Not indicated | Topical diclofenac only |
| Self-management | Exercise and cognitive behavioral therapy adherence | Every visit | Completed today | Physical therapy twice weekly and cognitive behavioral therapy weekly |
| Laboratory | 25-hydroxyvitamin D | About 3 months after starting repletion | Due | Recheck in about seven weeks |
Goal progress:
Guideline basis: CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022 (2022); Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians (2017); VA/DoD Clinical Practice Guideline for the Diagnosis and Treatment of Low Back Pain (2022); CMID: Clinical Monitoring Intelligence Database, osteoarthritis and depression monographs (2026)
Follow-up: Chronic pain review in two weeks for the second taper step. [S]